Peptides News and Research

RSS

ProJect Pharmaceutics opens laboratory facilities in Martinsried, Munich

ProJect Pharmaceutics started business operations and opened its laboratory facilities in the Biotech-cluster in Martinsried, near Munich. ProJect Pharmaceutics transforms proteins, peptides and delicate small molecules into pioneering drugs.

14 Dec 2010

New collaboration to develop vaccine to prevent malaria parasite from entering human liver

Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced today by global leaders in malaria research and vaccine development. The PATH Malaria Vaccine Initiative (MVI), Merck (known outside the US and Canada as MSD), and NYU Langone Medical Center are working together to evaluate an approach targeting a novel part of a major surface protein on the malaria parasite.

14 Dec 2010

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.

13 Dec 2010

Researchers generate insulin-secreting pancreatic islet cells from human SSCs

Insulin-secreting pancreatic islet cells have been generated from human spermatogonial stem cells (SSCs) directly isolated from human testicular tissue, researchers reported today at the American Association of Cell Biology 50th Annual Meeting in Philadelphia.

13 Dec 2010

New molecular tools show promise for cleansing brain of amyloid plaques

New molecular tools developed at the University of Michigan show promise for "cleansing" the brain of amyloid plaques, implicated in Alzheimer's disease.

10 Dec 2010

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.

9 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

9 Dec 2010

Nanoparticles could combat Listeria

A Purdue University research team developed a nanoparticle that can hold and release an antimicrobial agent as needed for extending the shelf life of foods susceptible to Listeria monocytogenes.

8 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

The Norwegian biopharmaceutical company Lytix Biopharma and the Korean biotechnology company KAEL-GemVax announced today the successful first treatment in the study of a combination of LTX-315 and GV1001 as anti-cancer vaccine therapy.

7 Dec 2010

Scientists have learned to mask bitterness of ginseng to improve consumers health

University of Illinois scientists have learned to mask the bitterness of ginseng, a common ingredient of energy drinks.

7 Dec 2010

Merrion Pharmaceuticals announces oral drug delivery Feasibility and Option agreement

Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world's top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion's patented GIPET technology to boost the bioavailablity of three of the 'big pharma' company's compounds.

6 Dec 2010

Dysfunction in blood vessels plays a role in Alzheimer's disease development

A dysfunction in the lining of blood vessels that is linked to cardiovascular illness also appears to play a role in the development of Alzheimer's disease, according to a study published in Circulation Research: Journal of the American Heart Association.

3 Dec 2010

Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes

Oramed Pharmaceuticals Inc. a developer of oral drug delivery solutions, announces a publication in the Journal of Diabetes Science and Technology's November issue describing evaluation of the company's glucagon-like peptide- (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.

2 Dec 2010

PepTcell changes name to SEEK

PepTcell, a leading UK privately-owned drug-discovery group, today announced it is changing its name to SEEK.

1 Dec 2010

Scripps Research Institute enters agreement with Aileron Therapeutics

The Scripps Research Institute and Aileron Therapeutics today announced that they have entered into an agreement that will add Scripps Research's "Click" chemistry to Aileron's proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide technology.

1 Dec 2010

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has begun Phase 1/2a clinical testing with its lead compound, Glymera(PB1023), in patients with Type 2 diabetes.

1 Dec 2010

Biotage adds ChemMatrix PEG resin to its purification product range

Biotage, a leading supplier of tools and technology for analytical and medicinal chemistry, announced the addition of ChemMatrix resins to its extensive offering of peptide synthesis and purification products.

30 Nov 2010

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.

30 Nov 2010

Peptides News and Research

ProJect Pharmaceutics opens laboratory facilities in Martinsried, Munich

New collaboration to develop vaccine to prevent malaria parasite from entering human liver

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Researchers generate insulin-secreting pancreatic islet cells from human SSCs

New molecular tools show promise for cleansing brain of amyloid plaques

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Nanoparticles could combat Listeria

Researchers synthesize wound-healing peptides

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

Scientists have learned to mask bitterness of ginseng to improve consumers health

Merrion Pharmaceuticals announces oral drug delivery Feasibility and Option agreement

Dysfunction in blood vessels plays a role in Alzheimer's disease development

Oramed announces publication of GLP-1 analog formulation in Journal of Diabetes

PepTcell changes name to SEEK

Scripps Research Institute enters agreement with Aileron Therapeutics

PhaseBio initiates Glymera Phase 1/2a clinical trial in patients with Type 2 diabetes

Biotage adds ChemMatrix PEG resin to its purification product range

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News